{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:33:50Z","timestamp":1793982830864,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.810"],"award-info":[{"award-number":["TTU TB 02.810"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.814"],"award-info":[{"award-number":["TTU TB 02.814"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.814"],"award-info":[{"award-number":["TTU TB 02.814"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.806"],"award-info":[{"award-number":["TTU TB 02.806"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.810"],"award-info":[{"award-number":["TTU TB 02.810"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.902"],"award-info":[{"award-number":["TTU TB 02.902"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TI 07.003"],"award-info":[{"award-number":["TI 07.003"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.705"],"award-info":[{"award-number":["TTU TB 02.705"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.710"],"award-info":[{"award-number":["TTU TB 02.710"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.806"],"award-info":[{"award-number":["TTU TB 02.806"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.810"],"award-info":[{"award-number":["TTU TB 02.810"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.814"],"award-info":[{"award-number":["TTU TB 02.814"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.902"],"award-info":[{"award-number":["TTU TB 02.902"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.709"],"award-info":[{"award-number":["TTU TB 02.709"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.813"],"award-info":[{"award-number":["TTU TB 02.813"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.705"],"award-info":[{"award-number":["TTU TB 02.705"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.710"],"award-info":[{"award-number":["TTU TB 02.710"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.806"],"award-info":[{"award-number":["TTU TB 02.806"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.810"],"award-info":[{"award-number":["TTU TB 02.810"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.814"],"award-info":[{"award-number":["TTU TB 02.814"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.901"],"award-info":[{"award-number":["TTU TB 02.901"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.902"],"award-info":[{"award-number":["TTU TB 02.902"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.705"],"award-info":[{"award-number":["TTU TB 02.705"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.710"],"award-info":[{"award-number":["TTU TB 02.710"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.806"],"award-info":[{"award-number":["TTU TB 02.806"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.810"],"award-info":[{"award-number":["TTU TB 02.810"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.814"],"award-info":[{"award-number":["TTU TB 02.814"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.901"],"award-info":[{"award-number":["TTU TB 02.901"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU TB 02.902"],"award-info":[{"award-number":["TTU TB 02.902"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1357 \u2013 391977956"],"award-info":[{"award-number":["SFB 1357 \u2013 391977956"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 91\/3731-FUGG"],"award-info":[{"award-number":["INST 91\/3731-FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TechnologieAllianzOberfranke"},{"name":"Leibniz Center for Photonics in Infection Research"},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["InfectControl 03TTA01"],"award-info":[{"award-number":["InfectControl 03TTA01"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["InfectControl 03TTA01"],"award-info":[{"award-number":["InfectControl 03TTA01"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The development of granulomas with central necrosis harboring\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (Mtb) is the hallmark of human tuberculosis (TB). New anti-TB therapies need to effectively penetrate the cellular and necrotic compartments of these lesions and reach sufficient concentrations to eliminate Mtb. BTZ-043 is a novel antibiotic showing good bactericidal activity in humans in a phase IIa trial. Here, we report on lesional BTZ-043 concentrations severalfold above the minimal-inhibitory-concentration and the substantial local efficacy of BTZ-043 in interleukin-13-overexpressing mice, which mimic human TB pathology of granuloma necrosis. High-resolution MALDI imaging further reveals that BTZ-043 diffuses and accumulates in the cellular compartment, and fully penetrates the necrotic center. This is the first study that visualizes an efficient penetration and accumulation of a clinical-stage TB drug in human-like centrally necrotizing granulomas and that also determines its lesional activity. Our results most likely predict a substantial bactericidal effect of BTZ-043 at these hard-to-reach sites in TB patients.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-56146-9","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T10:09:10Z","timestamp":1737194950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8384-9250","authenticated-orcid":false,"given":"Andreas","family":"R\u00f6mpp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Treu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kokesch-Himmelreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Marwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-9857","authenticated-orcid":false,"given":"Julia","family":"Dreisbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Aboutara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Hillemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Garrelts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-7464","authenticated-orcid":false,"given":"Paul J.","family":"Converse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Gerbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-8186","authenticated-orcid":false,"given":"Luzia","family":"Gyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Lemm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8703-5358","authenticated-orcid":false,"given":"Leon","family":"Gr\u00f6schel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Stemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-9889","authenticated-orcid":false,"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-9451","authenticated-orcid":false,"given":"Dominik","family":"Schwudke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7642-1835","authenticated-orcid":false,"given":"Michael","family":"Hoelscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-9146","authenticated-orcid":false,"given":"Christoph","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7883-4433","authenticated-orcid":false,"given":"Kerstin","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"56146_CR1","unstructured":"WHO. Global tuberculosis report. (WHO, Geneva, 2023)."},{"key":"56146_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMra1205429","volume":"367","author":"S Keshavjee","year":"2012","unstructured":"Keshavjee, S. & Farmer, P. E. Tuberculosis, drug resistance, and the history of modern medicine. N. Engl. J. Med. 367, 931\u2013936 (2012).","journal-title":"N. Engl. J. Med."},{"key":"56146_CR3","doi-asserted-by":"crossref","unstructured":"Dartois, V. A. & Rubin, E. J. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat. Rev. Microbiol., 20, 685\u2013701 (2022).","DOI":"10.1038\/s41579-022-00731-y"},{"key":"56146_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1574-6976.2012.00331.x","volume":"36","author":"M Gengenbacher","year":"2012","unstructured":"Gengenbacher, M. & Kaufmann, S. H. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev. 36, 514\u2013532 (2012).","journal-title":"FEMS Microbiol Rev."},{"key":"56146_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.3937","volume":"21","author":"B Prideaux","year":"2015","unstructured":"Prideaux, B. et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21, 1223\u20131227 (2015).","journal-title":"Nat. Med."},{"key":"56146_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrmicro3200","volume":"12","author":"V Dartois","year":"2014","unstructured":"Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159\u2013167 (2014).","journal-title":"Nat. Rev. Microbiol."},{"key":"56146_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/imr.12252","volume":"264","author":"A Lenaerts","year":"2015","unstructured":"Lenaerts, A., Barry, C. E. 3rd & Dartois, V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol. Rev. 264, 288\u2013307 (2015).","journal-title":"Immunol. Rev."},{"key":"56146_CR8","doi-asserted-by":"publisher","first-page":"613149","DOI":"10.3389\/fcimb.2021.613149","volume":"11","author":"HJ Yang","year":"2021","unstructured":"Yang, H. J., Wang, D., Wen, X., Weiner, D. M. & Via, L. E. One size fits all? not in in vivo modeling of tuberculosis chemotherapeutics. Front Cell Infect. Microbiol 11, 613149 (2021).","journal-title":"Front Cell Infect. Microbiol"},{"key":"56146_CR9","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.2353\/ajpath.2009.081075","volume":"174","author":"AV Pichugin","year":"2009","unstructured":"Pichugin, A. V., Yan, B. S., Sloutsky, A., Kobzik, L. & Kramnik, I. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am. J. Pathol. 174, 2190\u20132201 (2009).","journal-title":"Am. J. Pathol."},{"key":"56146_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/path.4399","volume":"234","author":"L Heitmann","year":"2014","unstructured":"Heitmann, L. et al. The IL-13\/IL-4Ralpha axis is involved in tuberculosis-associated pathology. J. Pathol. 234, 338\u2013350 (2014).","journal-title":"J. Pathol."},{"key":"56146_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","volume":"2","author":"SM Irwin","year":"2016","unstructured":"Irwin, S. M. et al. Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in mycobacterium tuberculosis infected C3HeB\/FeJ Mice. ACS Infect. Dis. 2, 251\u2013267 (2016).","journal-title":"ACS Infect. Dis."},{"key":"56146_CR12","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1021\/acs.analchem.1c03462","volume":"94","author":"J Kokesch-Himmelreich","year":"2022","unstructured":"Kokesch-Himmelreich, J. et al. Do anti-tuberculosis drugs reach their target?\u2500high-resolution matrix-assisted laser desorption\/ionization mass spectrometry imaging provides information on drug penetration into necrotic granulomas. Anal. Chem. 94, 5483\u20135492 (2022).","journal-title":"Anal. Chem."},{"key":"56146_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01588-21","volume":"66","author":"K Walter","year":"2022","unstructured":"Walter, K. et al. Interleukin-13-overexpressing mice represent an advanced preclinical model for detecting the distribution of antimycobacterial drugs within centrally necrotizing granulomas. Antimicrob. Agents Chemother. 66, e0158821 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56146_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00418-013-1097-6","volume":"139","author":"A R\u00f6mpp","year":"2013","unstructured":"R\u00f6mpp, A. & Spengler, B. Mass spectrometry imaging with high resolution in mass and space. Histochem. Cell Biol. 139, 759\u2013783 (2013).","journal-title":"Histochem. Cell Biol."},{"key":"56146_CR15","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1021\/ac1029049","volume":"83","author":"B Prideaux","year":"2011","unstructured":"Prideaux, B. et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. 83, 2112\u20132118 (2011).","journal-title":"Anal. Chem."},{"key":"56146_CR16","doi-asserted-by":"crossref","unstructured":"Boshoff, H. I. M. et al. Mtb-selective 5-aminomethyl oxazolidinone prodrugs: robust potency and potential liabilities. ACS Infect Dis 10, 1679\u20131695 (2024).","DOI":"10.1021\/acsinfecdis.4c00025"},{"key":"56146_CR17","doi-asserted-by":"publisher","first-page":"8841","DOI":"10.1007\/s00253-013-5218-x","volume":"97","author":"G Riccardi","year":"2013","unstructured":"Riccardi, G. et al. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. Appl Microbiol Biotechnol. 97, 8841\u20138848 (2013).","journal-title":"Appl Microbiol Biotechnol."},{"key":"56146_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.1171583","volume":"324","author":"V Makarov","year":"2009","unstructured":"Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801\u2013804 (2009).","journal-title":"Science"},{"key":"56146_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/emmm.201303575","volume":"6","author":"V Makarov","year":"2014","unstructured":"Makarov, V. et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol. Med. 6, 372\u2013383 (2014).","journal-title":"EMBO Mol. Med."},{"key":"56146_CR20","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1021\/jm500571f","volume":"57","author":"PS Shirude","year":"2014","unstructured":"Shirude, P. S. et al. Lead optimization of 1,4-azaindoles as antimycobacterial agents. J. Med. Chem. 57, 5728\u20135737 (2014).","journal-title":"J. Med. Chem."},{"key":"56146_CR21","doi-asserted-by":"crossref","unstructured":"Hariguchi, N. et al. OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 Inhibitor. Antimicrob Agents Chemother 64, e02020-19 (2020).","DOI":"10.1128\/AAC.02020-19"},{"key":"56146_CR22","doi-asserted-by":"publisher","unstructured":"Heinrich, N. et al. Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b\/2a trial. The Lancet Microbe https:\/\/doi.org\/10.1016\/j.lanmic.2024.07.015 (2024).","DOI":"10.1016\/j.lanmic.2024.07.015"},{"key":"56146_CR23","unstructured":"PAN-TB Collaboration to advance investigational tuberculosis drug regimens to phase 2 clinical trials. https:\/\/www.gatesmri.org\/wp-content\/uploads\/2022\/08\/PAN-TB-JDA-Press-Release-August-17-2022.pdf (2022)."},{"key":"56146_CR24","doi-asserted-by":"publisher","first-page":"886","DOI":"10.5588\/ijtld.21.0515","volume":"25","author":"MJ Boeree","year":"2021","unstructured":"Boeree, M. J. et al. UNITE4TB: a new consortium for clinical drug and regimen development for TB. Int J. Tuberc. Lung Dis. 25, 886\u2013889 (2021).","journal-title":"Int J. Tuberc. Lung Dis."},{"key":"56146_CR25","doi-asserted-by":"publisher","first-page":"13663","DOI":"10.1021\/ja106357w","volume":"132","author":"C Trefzer","year":"2010","unstructured":"Trefzer, C. et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-\u03b2-D-ribose 2\u2019-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 132, 13663\u201313665 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"56146_CR26","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1021\/ja211042r","volume":"134","author":"C Trefzer","year":"2012","unstructured":"Trefzer, C. et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-beta-D-ribofuranose 2\u2019-oxidase DprE1. J. Am. Chem. Soc. 134, 912\u2013915 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"56146_CR27","doi-asserted-by":"publisher","first-page":"11354","DOI":"10.1073\/pnas.1205735109","volume":"109","author":"SM Batt","year":"2012","unstructured":"Batt, S. M. et al. Structural basis of inhibition of mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl Acad. Sci. Usa. 109, 11354\u201311359 (2012).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"56146_CR28","doi-asserted-by":"publisher","first-page":"150ra121","DOI":"10.1126\/scitranslmed.3004395","volume":"4","author":"J Neres","year":"2012","unstructured":"Neres, J. et al. Structural basis for benzothiazinone-mediated killing of mycobacterium tuberculosis. Sci. Transl. Med. 4, 150ra121 (2012).","journal-title":"Sci. Transl. Med."},{"key":"56146_CR29","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1128\/AAC.01676-09","volume":"54","author":"MR Pasca","year":"2010","unstructured":"Pasca, M. R. et al. Clinical isolates of mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother. 54, 1616\u20131618 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56146_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00904-22","volume":"66","author":"NC Poulton","year":"2022","unstructured":"Poulton, N. C., Azadian, Z. A., DeJesus, M. A. & Rock, J. M. Mutations in rv0678 confer low-level resistance to benzothiazinone DprE1 inhibitors in mycobacterium tuberculosis. Antimicrob. Agents Chemother. 66, e0090422 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56146_CR31","doi-asserted-by":"publisher","first-page":"e0005223","DOI":"10.1128\/aac.00052-23","volume":"67","author":"DV Almeida","year":"2023","unstructured":"Almeida, D. V., Converse, P. J. & Nuermberger, E. L. Mutations in Rv0678 reduce susceptibility of mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371. Antimicrob. Agents Chemother. 67, e0005223 (2023).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56146_CR32","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1128\/AAC.02565-14","volume":"58","author":"SM Irwin","year":"2014","unstructured":"Irwin, S. M. et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob. Agents Chemother. 58, 4026\u20134034 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56146_CR33","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1128\/JCM.00547-11","volume":"49","author":"I Honeyborne","year":"2011","unstructured":"Honeyborne, I. et al. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J. Clin. Microbiol. 49, 3905\u20133911 (2011).","journal-title":"J. Clin. Microbiol."},{"key":"56146_CR34","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/nprot.2007.303","volume":"2","author":"I Hubatsch","year":"2007","unstructured":"Hubatsch, I., Ragnarsson, E. G. & Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2, 2111\u20132119 (2007).","journal-title":"Nat. Protoc."},{"key":"56146_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jac\/dku457","volume":"70","author":"SB Lakshminarayana","year":"2015","unstructured":"Lakshminarayana, S. B. et al. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J. Antimicrob. Chemother. 70, 857\u2013867 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"56146_CR36","unstructured":"ICH M9 on biopharmaceutics classification system based biowaivers, (European Medicines Agency, 2020)."},{"key":"56146_CR37","doi-asserted-by":"crossref","unstructured":"Blanc, L. et al. High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types. Elife 7, e41115 (2018).","DOI":"10.7554\/eLife.41115"},{"key":"56146_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12866-015-0431-7","volume":"15","author":"LH Cazares","year":"2015","unstructured":"Cazares, L. H. et al. Heat fixation inactivates viral and bacterial pathogens and is compatible with downstream MALDI mass spectrometry tissue imaging. BMC Microbiol 15, 101 (2015).","journal-title":"BMC Microbiol"},{"key":"56146_CR39","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1021\/jasms.1c00205","volume":"11","author":"N Wang","year":"2021","unstructured":"Wang, N. et al. On-Slide Heat Sterilization Enables Mass Spectrometry Imaging of Tissue Infected with High-Threat Pathogens Outside of Biocontainment: A Study Directed at Mycobacterium tuberculosis. J. Am. Soc. Mass Spectrom. 11, 2664\u20132674 (2021).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"56146_CR40","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1021\/jasms.0c00235","volume":"31","author":"A Treu","year":"2020","unstructured":"Treu, A., Kokesch-Himmelreich, J., Walter, K., H\u00f6lscher, C. & R\u00f6mpp, A. Integrating high-resolution MALDI imaging into the development pipeline of anti-tuberculosis drugs. J. Am. Soc. Mass Spectrom. 31, 2277\u20132286 (2020).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"56146_CR41","doi-asserted-by":"publisher","first-page":"10099","DOI":"10.1021\/ac400892z","volume":"85","author":"MR Groseclose","year":"2013","unstructured":"Groseclose, M. R. & Castellino, S. A mimetic tissue model for the quantification of drug distributions by MALDI imaging mass spectrometry. Anal. Chem. 85, 10099\u201310106 (2013).","journal-title":"Anal. Chem."},{"key":"56146_CR42","doi-asserted-by":"publisher","first-page":"e1000204","DOI":"10.1371\/journal.ppat.1000204","volume":"4","author":"P Peyron","year":"2008","unstructured":"Peyron, P. et al. Foamy macrophages from tuberculous patients\u2019 granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog. 4, e1000204 (2008).","journal-title":"PLoS Pathog."},{"key":"56146_CR43","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman, S. E. et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N. Engl. J. Med. 384, 1705\u20131718 (2021).","journal-title":"N. Engl. J. Med."},{"key":"56146_CR44","doi-asserted-by":"crossref","unstructured":"Nuermberger, E. L. et al. Preclinical Efficacy Testing of New Drug Candidates. Microbiol Spectr 5, 1128 (2017).","DOI":"10.1128\/microbiolspec.TBTB2-0034-2017"},{"key":"56146_CR45","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nri.2017.69","volume":"17","author":"AM Cadena","year":"2017","unstructured":"Cadena, A. M., Fortune, S. M. & Flynn, J. L. Heterogeneity in tuberculosis. Nat. Rev. Immunol. 17, 691\u2013702 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"56146_CR46","doi-asserted-by":"publisher","first-page":"4245028","DOI":"10.1155\/2016\/4245028","volume":"2016","author":"C Holscher","year":"2016","unstructured":"Holscher, C. et al. A mutation in IL4RA is associated with the degree of pathology in human TB patients. Mediators Inflamm. 2016, 4245028 (2016).","journal-title":"Mediators Inflamm."},{"key":"56146_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09177-2","volume":"7","author":"M Gengenbacher","year":"2017","unstructured":"Gengenbacher, M. et al. NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. Sci. Rep. 7, 8853 (2017).","journal-title":"Sci. Rep."},{"key":"56146_CR48","doi-asserted-by":"crossref","unstructured":"Ramey, M. E. et al. Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB\/FeJ mouse tuberculosis model. Antimicrob Agents Chemother, e0059723 (2023).","DOI":"10.1128\/aac.00597-23"},{"key":"56146_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00216-011-4990-7","volume":"401","author":"A R\u00f6mpp","year":"2011","unstructured":"R\u00f6mpp, A., Guenther, S., Takats, Z. & Spengler, B. Mass spectrometry imaging with high resolution in mass and space (HR(2) MSI) for reliable investigation of drug compound distributions on the cellular level. Anal. Bioanal. Chem. 401, 65\u201373 (2011).","journal-title":"Anal. Bioanal. Chem."},{"key":"56146_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00506-21","volume":"65","author":"JP Ernest","year":"2021","unstructured":"Ernest, J. P. et al. Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. Antimicrob. Agents Chemother. 65, e0050621 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56146_CR51","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ijms.2014.08.024","volume":"377","author":"B Prideaux","year":"2015","unstructured":"Prideaux, B. et al. Mass spectrometry imaging of levofloxacin distribution in TB-infected pulmonary lesions by MALDI-MSI and continuous liquid microjunction surface sampling. Int. J. Mass spectrom. 377, 699\u2013708 (2015).","journal-title":"Int. J. Mass spectrom."},{"key":"56146_CR52","doi-asserted-by":"publisher","first-page":"e1005650","DOI":"10.1371\/journal.pcbi.1005650","volume":"13","author":"E Pienaar","year":"2017","unstructured":"Pienaar, E. et al. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. PLoS Comput. Biol. 13, e1005650 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"56146_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","volume":"17","author":"MJ Boeree","year":"2017","unstructured":"Boeree, M. J. et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect. Dis. 17, 39\u201349 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"56146_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00024-21","volume":"65","author":"O Egbelowo","year":"2021","unstructured":"Egbelowo, O. et al. Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits. Antimicrob. Agents Chemother. 65, e0002421 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56146_CR55","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1242\/dmm.019570","volume":"8","author":"SM Irwin","year":"2015","unstructured":"Irwin, S. M. et al. Presence of multiple lesion types with vastly different microenvironments in C3HeB\/FeJ mice following aerosol infection with Mycobacterium tuberculosis. Dis. Model. Mech. 8, 591\u2013602 (2015).","journal-title":"Dis. Model. Mech."},{"key":"56146_CR56","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1073\/pnas.1424563112","volume":"112","author":"M Datta","year":"2015","unstructured":"Datta, M. et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc. Natl Acad. Sci. Usa. 112, 1827\u20131832 (2015).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"56146_CR57","unstructured":"Savic, R. PAN-TB Strategy for Accelerating Prioritization of PAN-TB Drug Combinations: Optimized Nonclinical Study Designs in a Model-Based Framework. (The Union World Conference on Lung Health, Paris (2023)."},{"key":"56146_CR58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1084\/jem.188.2.399","volume":"188","author":"CL Emson","year":"1998","unstructured":"Emson, C. L., Bell, S. E., Jones, A., Wisden, W. & McKenzie, A. N. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J. Exp. Med. 188, 399\u2013404 (1998).","journal-title":"J. Exp. Med."},{"key":"56146_CR59","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.4049\/jimmunol.1501012","volume":"195","author":"K Walter","year":"2015","unstructured":"Walter, K. et al. Cathepsin G in experimental tuberculosis: relevance for antibacterial protection and potential for immunotherapy. J. Immunol. 195, 3325\u20133333 (2015).","journal-title":"J. Immunol."},{"key":"56146_CR60","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1128\/AAC.05293-11","volume":"55","author":"R Tasneen","year":"2011","unstructured":"Tasneen, R. et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55, 5485\u20135492 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"56146_CR61","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/anie.201609737","volume":"56","author":"F Kloss","year":"2017","unstructured":"Kloss, F. et al. In vivo dearomatization of the potent antituberculosis agent BTZ043 via meisenheimer complex formation. Angew. Chem. Int Ed. Engl. 56, 2187\u20132191 (2017).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"56146_CR62","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/BF02111499","volume":"13","author":"CB Inderlied","year":"1994","unstructured":"Inderlied, C. B. Antimycobacterial susceptibility testing: present practices and future trends. Eur. J. Clin. Microbiol Infect. Dis. 13, 980\u2013993 (1994).","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"56146_CR63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13361-017-1809-6","volume":"29","author":"MT Bokhart","year":"2018","unstructured":"Bokhart, M. T., Nazari, M., Garrard, K. P. & Muddiman, D. C. MSiReader v1.0: evolving open-source mass spectrometry imaging software for targeted and untargeted analyses. J. Am. Soc. Mass Spectrom. 29, 8\u201316 (2018).","journal-title":"J. Am. Soc. Mass Spectrom."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56146-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56146-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56146-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T22:06:32Z","timestamp":1737237992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56146-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56146"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56146-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2615777\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NH has received a grant for conducting a study on delpazolid, a TB drug candidate, from LegoChem biosciences, to his institution. ELN received research funding from TB Alliance, Gates Medical Research Institute, and Janssen to his institution. MH, NH, and JD are employees of LMU Klinikum the institution that is developing BTZ-043 and have received funding from the German government. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"826"}}